Novel treatment strategies for tuberculosis are urgently needed. Many different preclinical
models assessing anti-tuberculosis drug activity are available, but it is yet unclear which
combination of models is most predictive of clinical treatment efficacy. The aim of this study
was to determine the role of our in vitro time kill-kinetics assay as an asset to a predictive
preclinical modeling framework assessing anti-tuberculosis drug activity. The concentration-
and time-dependent mycobacterial killing capacities of six anti-tuberculosis drugs were …